Fund Overlap
See which holdings any two equity ETFs have in common, along with top differences in exposure.
For overlap across multiple ETFs use Portfolio Builder
OVERLAP
20%
OVERLAP
BY WEIGHT
10
# OF OVERLAPPING
HOLDINGS
FTXH
49
HOLDINGS
21%
ALSO IN CANC
CANC
50
HOLDINGS
20%
ALSO IN FTXH
SECTOR DRIFT (FTXH minus CANC)
OVERLAPPING HOLDINGS
Top 5 only shown here. Please log-in or sign up for a Basic (Free) membership to view the complete list.
| Company | Weight in FTXH |
Weight in CANC |
Overlap | |
|---|---|---|---|---|
 |
BRISTOL-MYERS SQUIBB CO | 6.1% | 3.4% | 3.4% |
|
ABBVIE INC | 7.5% | 2.9% | 2.9% |
|
ELI LILLY & CO | 2.7% | 3.6% | 2.7% |
|
AMGEN INC | 3.7% | 2.4% | 2.4% |
|
MERCK & CO. INC. | 6.9% | 2.2% | 2.2% |
FTXH Overweight Relative to CANC
|
JOHNSON & JOHNSON | 8.3% |
|
PFIZER INC | 7.3% |
|
MERCK & CO. INC. | 4.7% |
|
ABBVIE INC | 4.6% |
|
VIATRIS, INC. | 4.1% |
|
UNITED THERAPEUTICS CORP | 3.7% |
|
BIOGEN IDEC INC | 3.7% |
|
ZOETIS INC | 3.5% |
 |
JAZZ PHARMACEUTICALS PLC | 3.1% |
|
BRISTOL-MYERS SQUIBB CO | 2.7% |
FTXH Underweight Relative to CANC
|
BRIDGEBIO PHARMA, INC. | -5.2% |
 |
ROCHE HOLDINGS LTD-SPONS ADR | -4.9% |
|
REVOLUTION MEDICINES, INC. | -4.8% |
 |
MERUS N.V. | -4.5% |
 |
ASTRAZENECA PLC | -4.3% |
|
SUMMIT THERAPEUTICS INC | -4.2% |
|
NOVARTIS AG | -4.2% |
 |
GENMAB A/S SPONSORED ADR | -3.8% |
|
ARCELLX, INC. | -3.3% |
|
NUVALENT, INC. CLASS A | -3.2% |